Journal
CELLS
Volume 11, Issue 20, Pages -Publisher
MDPI
DOI: 10.3390/cells11203205
Keywords
B-ALL; leukemia; PCNA; alternative splicing
Categories
Funding
- SEPCONACyT Mexico [243233]
- FOSISS grant [272633]
- Fiscal Funds from the Instituto Nacional de Pediatria, SSA [027/2015, 060/2016]
Ask authors/readers for more resources
Leukemia is a common childhood malignancy in Mexico with low treatment success rate. The study found that there are multiple transcript variants of the proliferating cell nuclear antigen (PCNA) gene, and some of these variants are expressed at significantly low levels in acute lymphoblastic leukemia patients, which could serve as potential molecular markers for relapse.
Leukemia is the most common childhood malignancy in Mexico, representing more than 50% of all childhood cancers. Although treatment leads to a survival of up to 90% in developing countries, in our country, it is less than 65%. Additionally, similar to 30% of patients relapse with poor prognosis. Alternative splicing plays an important role in transcriptome diversity and cellular biology. This mechanism promotes an increase in the assortment of proteins with potentially distinct functions from a single gene. The proliferating cell nuclear antigen (PCNA) gene encodes two transcripts for the same protein of 261 amino acids, which is associated with several important cellular processes and with several types of cancer. However, the diversity of the transcript variants expressed in this condition is not clear. Then, we used microarray gene expression to identify changes in the exon expression level of PCNA. The data were validated using RT-PCR and Sanger sequencing, and three additional transcripts (PCNA_V3, PCNA_V4, and PCNA_V5) were identified. Computational analyses were used to determine the potential proteins resulting, their structure, and interactions with PCNA native protein and themselves. Additionally, the PCNA transcript variants were inhibited using specific siRNA, determining that their inhibition contributes to the malignant characteristics in vitro. Finally, we quantified the PCNA transcript variants in acute lymphoblastic leukemia samples and identified their expression in this disease. Based on the clinical characteristics, we determined that PCNA_V2 and PCNA_V4 are expressed at significantly low levels in relapsed B-ALL patients. We conclude that the low expression of PCNA_V2 and PCNA_V4 could be a potential molecular marker of relapse in acute lymphoblastic leukemia patients.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available